Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, Kondoh Y, Imai K
First Department of Internal Medicine, Sapporo Medical University, Japan.
Cancer Lett. 1998 Jul 17;129(2):229-34. doi: 10.1016/s0304-3835(98)00112-8.
KAI1 was immunohistochemically detected in the lower part of fundic glands and intestinal metaplasia in non-cancerous gastric tissues, while only 11.0% (8/73) of cancerous tissues were shown to be positive. The relationship between various clinicopathological characteristics of patients with gastric cancer and KAI1 expression in their tumors was then analyzed to reveal that the incidence of positivity was 16.6% (8/48) of patients with stage Ia-IIIa and 0% (0/25) of patients with stage IIIb-IVb (P < 0.05) and that the incidence of peritoneal or hepatic metastasis tended to be lower in KAI1-positive tumors than in negative ones. These results suggest that decreased KAI1 expression may be related to the progression of gastric cancer.
在非癌性胃组织的胃底腺下部和肠化生中通过免疫组织化学检测到KAI1，而癌组织中仅有11.0%（8/73）呈阳性。随后分析了胃癌患者的各种临床病理特征与肿瘤中KAI1表达之间的关系，结果显示，Ia - IIIa期患者的阳性率为16.6%（8/48），IIIb - IVb期患者的阳性率为0%（0/25）（P < 0.05），并且KAI1阳性肿瘤的腹膜或肝转移发生率往往低于阴性肿瘤。这些结果表明，KAI1表达降低可能与胃癌进展有关。
